

Robert J Moots

List of Publications by Citations

Source: <https://exaly.com/author-pdf/966435/robert-j-moots-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

3,672
citations

31
h-index

60
g-index

108
ext. papers

4,729
ext. citations

4.9
avg, IF

5.6
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 90 | Neutrophil function in inflammation and inflammatory diseases. <i>Rheumatology</i> , 2010 , 49, 1618-31 | 3.9 | 515 |
| 89 | The multifactorial role of neutrophils in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 593-601 | 8.1 | 311 |
| 88 | 2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 808-818 | 2.4 | 277 |
| 87 | Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017 , 390, 457-468 | 4.0 | 227 |
| 86 | Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. <i>Journal of Biological Chemistry</i> , 2004 , 279, 26915-21 | 5.4 | 187 |
| 85 | Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1440-1450 | 9.5 | 122 |
| 84 | Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. <i>Rheumatology</i> , 2014 , 53, 1321-31 | 3.3 | 110 |
| 83 | Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 979-84 | 2.4 | 99 |
| 82 | The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1167-1178 | 2.4 | 80 |
| 81 | Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. <i>Rheumatology</i> , 2012 , 51, 451-9 | 3.9 | 76 |
| 80 | Synovial fluid neutrophils transcribe and express class II major histocompatibility complex molecules in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2796-806 | | 76 |
| 79 | Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. <i>Rheumatology</i> , 2015 , 54, 188-93 | 3.9 | 73 |
| 78 | The dual effects of TNFalpha on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. <i>Blood</i> , 2008 , 111, 878-84 | 2.2 | 72 |
| 77 | RNA-seq reveals activation of both common and cytokine-specific pathways following neutrophil priming. <i>PLoS ONE</i> , 2013 , 8, e58598 | 3.7 | 72 |
| 76 | Low-density granulocytes: functionally distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective TNF signalling. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 599-611 | 6.5 | 68 |
| 75 | Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019 , 10, 423 | 8.4 | 65 |
| 74 | Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1362-8 | 2.4 | 63 |

| | | | |
|----|---|-----|----|
| 73 | The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. <i>PLoS ONE</i> , 2017 , 12, e0175207 | 3.7 | 63 |
| 72 | Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017 , 19, 37 | 4.9 | 62 |
| 71 | Changes in expression of membrane TNF, NF- κ B activation and neutrophil apoptosis during active and resolved inflammation. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 537-43 | 2.4 | 60 |
| 70 | Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018 , 57, 2200-2212 | 3.9 | 57 |
| 69 | Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 412-416 | 2.4 | 53 |
| 68 | Behcet's disease. <i>Clinical Medicine</i> , 2017 , 17, 71-77 | 1.9 | 50 |
| 67 | Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016 , 2, e000282 | 5.9 | 46 |
| 66 | The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. <i>Rheumatology</i> , 2012 , 51, 2252-61 | 3.9 | 43 |
| 65 | Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 305-317 | 4.0 | 42 |
| 64 | Inflammatory arthritis in HIV positive patients: A practical guide. <i>BMC Infectious Diseases</i> , 2016 , 16, 100 | 4 | 41 |
| 63 | Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. <i>Rheumatology</i> , 2011 , 50, 1672-83 | 3.9 | 39 |
| 62 | Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 752-762 | 5.3 | 38 |
| 61 | Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. <i>Rheumatology</i> , 2014 , 53, 1595-603 | 3.9 | 38 |
| 60 | Etanercept for the treatment of rheumatoid arthritis. <i>Immunotherapy</i> , 2018 , 10, 433-445 | 3.8 | 36 |
| 59 | Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018 , 20, 57 | 4.9 | 28 |
| 58 | Whose Gene Is It Anyway? The Effect of Preparation Purity on Neutrophil Transcriptome Studies. <i>PLoS ONE</i> , 2015 , 10, e0138982 | 3.7 | 28 |
| 57 | Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017 , 56, 541-549 | 3.9 | 28 |
| 56 | Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 77 | 2.8 | 24 |

| | | | |
|----|---|-----|----|
| 55 | Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps. <i>Frontiers in Immunology</i> , 2020 , 11, 584116 | 8.4 | 24 |
| 54 | Comorbidity burden in axial spondyloarthritis: a cluster analysis. <i>Rheumatology</i> , 2019 , 58, 1746-1754 | 3.9 | 23 |
| 53 | Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 785-795 | 6.5 | 23 |
| 52 | Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. <i>BioDrugs</i> , 2018 , 32, 193-199 | 7.9 | 20 |
| 51 | Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2020 , 59, iv47-iv57 | 3.9 | 17 |
| 50 | Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018 , 20, 84 | 4.9 | 17 |
| 49 | Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients. <i>Drugs and Aging</i> , 2017 , 34, 255-264 | 4.7 | 16 |
| 48 | Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). <i>Rheumatology</i> , 2019 , 58, 811-819 | 3.9 | 16 |
| 47 | Mavrilimumab, a human monoclonal GM-CSF receptor-1 antibody for the management of rheumatoid arthritis: a novel approach to therapy. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1661-854 | 5.4 | 15 |
| 46 | Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. <i>Rheumatology</i> , 2019 , 58, 2025-2030 | 3.9 | 14 |
| 45 | Cutaneous immunopathology of long-standing complex regional pain syndrome. <i>European Journal of Pain</i> , 2015 , 19, 1516-26 | 3.7 | 14 |
| 44 | Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase III/IV trial. <i>RMD Open</i> , 2019 , 5, e001040 | 5.9 | 13 |
| 43 | Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 737-45 | 2.2 | 12 |
| 42 | Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies. <i>Arthritis Care and Research</i> , 2020 , 72, 591-599 | 4.7 | 11 |
| 41 | Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. <i>Rheumatology International</i> , 2017 , 37, 239-244 | 3.6 | 10 |
| 40 | Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e000885 | 5.9 | 9 |
| 39 | Resveratrol and N-acetylcysteine influence redox balance in equine articular chondrocytes under acidic and very low oxygen conditions. <i>Free Radical Biology and Medicine</i> , 2015 , 86, 57-64 | 7.8 | 9 |
| 38 | Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?—observations from the UK JSLE Cohort Study. <i>Rheumatology</i> , 2021 , 60, 5271-5281 | 3.9 | 8 |

| | | | |
|----|---|-----|---|
| 37 | Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2016 , 55, 544-52 | 3.9 | 7 |
| 36 | THE CHALLENGES OF RARE RHEUMATIC DISEASES/19. CHALLENGES OF DIAGNOSING AND MANAGING PATIENTS WITH RARE DISEASES. <i>Rheumatology</i> , 2017 , 56, | 3.9 | 7 |
| 35 | Safety and efficacy of subcutaneous ivalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. <i>Lancet, The</i> , 2021 , | 4.0 | 7 |
| 34 | Development of a Rheumatology-specific Patient Concerns Inventory and Its Use in the Rheumatology Outpatient Clinic Setting. <i>Journal of Rheumatology</i> , 2016 , 43, 779-87 | 4.1 | 6 |
| 33 | Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries. <i>Rheumatology</i> , 2012 , 51, 393-6 | 3.9 | 6 |
| 32 | Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1687-99 | 5.9 | 6 |
| 31 | A fistful of T cells. <i>Rheumatology</i> , 1998 , 37, 602-11 | 3.9 | 6 |
| 30 | Mycophenolate for persistent complex regional pain syndrome, a parallel, open, randomised, proof of concept trial. <i>Scandinavian Journal of Pain</i> , 2018 , 18, 29-37 | 1.9 | 6 |
| 29 | Fibromyalgia in Behçet's disease: a narrative review. <i>British Journal of Pain</i> , 2017 , 11, 97-101 | 2.1 | 4 |
| 28 | Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab. <i>Rheumatology</i> , 2015 , 54, 743-4 | 3.9 | 4 |
| 27 | Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 177 | 5.7 | 4 |
| 26 | Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1287-1288 | 2.4 | 3 |
| 25 | APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without suppressing antimicrobial ability, and inhibits TNF expression and signalling. <i>Inflammopharmacology</i> , 2020 , 28, 1223-1235 | 5.1 | 3 |
| 24 | An update on the general management approach to common vasculitides. <i>Clinical Medicine</i> , 2020 , 20, 572-579 | 1.9 | 3 |
| 23 | Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. <i>Rheumatology</i> , 2021 , 60, 4158-4165 | 3.9 | 3 |
| 22 | Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. <i>Rheumatology</i> , 2021 , 60, 3189-3198 | 3.9 | 3 |
| 21 | Internalization of Neutrophil-Derived Microvesicles Modulates TNF- α -stimulated Proinflammatory Cytokine Production in Human Fibroblast-Like Synoviocytes. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 3 |
| 20 | Type I interferon regulates cytokine-delayed neutrophil apoptosis, reactive oxygen species production and chemokine expression. <i>Clinical and Experimental Immunology</i> , 2021 , 203, 151-159 | 6.2 | 3 |

| | | | |
|----|---|-----|---|
| 19 | Behcet's syndrome. <i>BMJ, The</i> , 2009 , 339, b3876 | 5.9 | 2 |
| 18 | Biomarkers for treatment response in rheumatoid arthritis: Where are they?. <i>Rheumatology and Immunology Research</i> , 2020 , 1, 1-3 | 0.2 | 2 |
| 17 | Measuring disease activity and response to treatment in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 135-145 | 5.1 | 2 |
| 16 | Anti-TNF biosimilars in rheumatology: the end of an era?. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 29-36 | 5.4 | 2 |
| 15 | Behçet's syndrome in children and young people in the United Kingdom and the Republic of Ireland: a prospective epidemiological study. <i>Rheumatology</i> , 2021 , 60, 4728-4736 | 3.9 | 2 |
| 14 | 012 Proteomic analysis of neutrophil extracellular traps in rheumatoid arthritis and systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, | 3.9 | 1 |
| 13 | Expanded population of CD1d-restricted V α 4+ cells in a patient with active rheumatoid arthritis. <i>Clinical Immunology</i> , 2014 , 150, 140-2 | 9 | 1 |
| 12 | FRI0100 Treat to target: defining the optimum target to prevent radiographic erosion progression during the first year of treatment in an early rheumatoid arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A403.3-A404 | 2.4 | 1 |
| 11 | SAT0049 Obesity is Associated with Reduced Improvement in Functional Disability After 1 Year of Treatment: Results from an Inception Early Rheumatoid Arthritis Cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A596.2-A596 | 2.4 | 1 |
| 10 | OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN'S SYNDROME. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 187.1-188 | 2.4 | 1 |
| 9 | OP0220 ASSESSING THE EFFECT OF INCREASED BODY MASS INDEX ON RESPONSE TO TNF INHIBITORS IN ESTABLISHED RHEUMATOID ARTHRITIS: RESULTS FROM THE METEOR DATABASE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 137.1-137 | 2.4 | 0 |
| 8 | Isolation of Microvesicles from Human Circulating Neutrophils. <i>Bio-protocol</i> , 2021 , 11, e3119 | 0.9 | 0 |
| 7 | Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. <i>Rheumatology</i> , 2021 , 60, 5734-5742 | 3.9 | 0 |
| 6 | FRI0096 Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A402.1-A402 | 2.4 | |
| 5 | Manifestations of systemic sclerosis necessitate a holistic approach to patient care: a case report. <i>Musculoskeletal Care</i> , 2010 , 8, 164-7 | 1.6 | |
| 4 | POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 593-594 | 2.4 | |
| 3 | Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 679-84 | 2.2 | |
| 2 | A novel treatment in the management of genital ulceration in Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 121, 158 | 2.2 | |

- 1 Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective